The July/August 2020 issue of Pharmafocus is available to read free online now!
With many countries past the peak of their national COVID-19 outbreaks, pressure to end more stringent lockdown measures is rising. The cost to national economies is high as social distancing measures stifle business, and many governments are now relaxing their rules in a bid to return to normality. But the science gives a blunt warning on the perils of ending lockdown early. From Europe, to the UK, to Brazil, the threat of a second spike in cases of the disease looms and requires a careful approach.
Fortunately, a number of treatments continue to see promise, with dexamethasone becoming the first therapy shown to reduce mortality in COVID-19 patients, while Gilead plans an inhaled formulation of its encouraging antiviral drug remdesivir.
This month, we also have features on the economic burden of the ground-breaking CAR T cancer therapy, and why sustainability is such an imperative issue for pharmaceutical and biotech firms today.
And elsewhere in the issue, we speak to Dr Arthur Roach to learn more about the work being done at Parkinson’s UK’s “virtual biotech”, a drug development arm of the charity designed to fund promising early candidates to treat the disease, and Dr Debra Barker, Chief Medical Officer at Polyneuron Pharmaceuticals, looks back on her career in our Working Life focus.
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …